INFECTIONS IN OCRELIZUMAB RECIPIENTS FROM PHASE III STUDIES

被引：0
|
作者：
Gavin, Giovannoni [1 ]
Hans-Peter, Hartung [2 ]
Giancarlo, Comi [3 ]
Jerome, de Seze [4 ]
Bernhard, Hemmer [5 ]
Ludwig, Kappos [6 ]
Xavier, Montalban [7 ]
Krzysztof, Selmaj [8 ]
Nicole, Mairon [9 ]
Jerry, Wolinsky [10 ]
机构：
[1] Queen Mary Univ London, London, England
[2] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Hosp Strasbourg, Strasbourg, France
[5] Tech Univ Munich, Munich, Germany
[6] Univ Hosp Basel, Basel, Switzerland
[7] Univ Toronto, Toronto, ON, Canada
[8] Med Univ Lodz, Lodz, Poland
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] UTHealth, McGovern Med Sch, Houston, TX USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2018年 / 89卷 / 10期
关键词：
D O I：
10.1136/jnnp-2018-ABN.92
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WED 187
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Results from pooled Phase III studies of ulipristal acetate for emergency contraception
    Moreau, Caroline
    Trussell, James
    CONTRACEPTION, 2012, 86 (06) : 673 - 680
  • [42] Ocrelizumab/rituximabB-lymphopenia and infections: 4 case reports
    Reactions Weekly, 2012, 1427 (1) : 35 - 35
  • [43] RESULTS FROM POOLED PHASE III STUDIES OF ULIPRISTAL ACETATE FOR EMERGENCY CONTRACEPTION
    Moreau, C.
    Trussell, J.
    CONTRACEPTION, 2011, 84 (03) : 308 - 308
  • [44] Exacerbation utilities and durations by type: estimates from Phase III benralizumab studies
    Brannman, Lance
    Ouwens, Mario
    Golam, Sarowar Muhammad
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [45] Signals from SABR-COMET time to move on to phase III studies
    Milano, Michael T.
    Chowdhry, Amit K.
    Salama, Joseph K.
    Chmura, Steven J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [46] MnDPDP for MR imaging of the liver - Results from the European phase III studies
    Torres, CG
    Lundby, B
    Sterud, AT
    McGill, S
    Gordon, PB
    Bjerknes, HS
    ACTA RADIOLOGICA, 1997, 38 (04) : 631 - 637
  • [47] Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
    Cree, Bruce A. C.
    Pradhan, Ashish
    Pei, Jinglan
    Williams, Mitzi J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [48] Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies
    Hauser, S. L.
    Comi, G. C.
    Hartung, H. -P.
    Selmaj, K.
    Traboulsee, A.
    Bar-Or, A.
    Arnold, D. L.
    Klingelschmitt, G.
    Kakarieka, A.
    Lublin, F.
    Garren, H.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 61 - 62
  • [49] Utilization, safety, and tolerability of ocrelizumab: data from the providence ocrelizumab registry
    Smoot, K.
    Stuchiner, T.
    Grote, L.
    Chen, C.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 386 - 386
  • [50] Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies
    Hauser, Stephen L.
    Comi, Giancarlo C.
    Hartung, Hans-Peter
    Selmaj, Krzysztof
    Traboulsee, Anthony
    Bar-Or, Amit
    Arnold, Douglas L.
    Lublin, Fred
    Klingelschmitt, Gaelle
    Masterman, Donna
    Fontoura, Paulo
    Chin, Peter
    Garren, Hideki
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 18
12345